Wolfe Research analyst Justin Lake downgraded Cano Health to Peer Perform from Outperform without a price target. The an last cites the company’s “challenging” capital position and lack of forward visibility for the downgrade. Heading into 2023, “the path forward for Cano is difficult to determine,” Lake tells investors in a research note.
previous post